TABLE 3.
Summary of Outcomes in the REP 301‐LTF Study
| Follow‐Up Completed | Participants at 1 year* | Participants at 3.5 years | |
|---|---|---|---|
| Clinical response | Normal ALT | 8/11 (73%) | 8/11 (73%) |
| Normalization † of liver stiffness | 3/11 (27%) | 4/11 (36%) | |
| Continually declining ‡ liver stiffness | 2/11 (18%) | 2/11 (18%) | |
| HBsAg response | <100 IU/mL | 5/11 (45%) | 5/11 (45%) |
| <10 IU/mL | 5/11 (45%) | 5/11 (45%) | |
| <1 IU/mL | 5/11 (45%) | 5/11 (45%) | |
| <0.05 IU/mL | 5/11 (45%) | 4/11 (36%) | |
| ≤0.005 IU/mL | 4/11 (36%) | 4/11 (36%) | |
| Seroconversion | 5/11 (42%) | 4/11 (36%) | |
| HDV RNA response | >2 log10 reduction from baseline | 9/11 (82%) | 9/11 (82%) |
| TND | 7/11 (65%) | 7/11 (64%) | |
Data show number (percentage) of participants out of total.
*
Previously published.( 19 )
†
Liver median stiffness ≤7 kpa.
‡
Liver median stiffness <baseline and continually declining during follow‐up.